<DOC>
	<DOCNO>NCT00753246</DOCNO>
	<brief_summary>Determination efficiency nimotuzumab adult glioblastoma multiforma</brief_summary>
	<brief_title>Nimotuzumab Adults With Glioblastoma Multiforma</brief_title>
	<detailed_description>The objective present study comparison treatment patient newly diagnose glioblastoma multiforme grade IV . Patients randomize one two arm include . Patients randomly assign arm A receive Nimotuzumab ( OSAG 101 ) plus Temozolomide concomitant standard radiotherapy . Patients randomise arm B receive standard radiotherapy plus Temozolomide treatment .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Patient sign informed consent Newly diagnose , histologically confirm glioblastoma multiforme grade IV Condition measurable MRI least one dimension Age 1870 KarnofskyIndex &gt; 40 Treatment study center Female patient childbearing potential must negative pregnancy test within one week inclusion trial . Those female male patient admit study must use reliable method contraception . Adequate haematological , renal hepatic function : Leucocytes &gt; 2.0x10^9/l Hb &gt; 10g/dl Billirubin total &lt; 2.5x upper limit normal ( ULN ) Creatinin i.S . &lt; 1.5x ULN AST ( GOT ) /ALT ( GPT ) &lt; 5x ULN Patients history anaphylactic reaction murine humanize antibody Patients evidence second malignancy Patients pregnant patient refuse adequate contraceptive precaution ( female male ) trial Pregnancy lactation Other condition consider investigator sound reason disqualification enrolment study : potential non compliance protocol requirement No MRI tumour evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>glioblastoma multiforma</keyword>
</DOC>